Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2010 April ; 19(4): 1033–1041. doi:10.1158/1055-9965.EPI-09-0975.

Analgesic use and sex steroid hormone concentrations in postmenopausal women

Margaret A. Gates^{1,2}, Shelley S. Tworoger^{1,2}, A. Heather Eliassen¹, Stacey A. Missmer^{1,2,3}, and Susan E. Hankinson^{1,2}

¹ Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

² Department of Epidemiology, Harvard School of Public Health, Boston, MA

³ Department of Obstetrics, Gynecology, and Reproductive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Abstract

Prior epidemiologic studies suggest that regular use of analgesics may decrease risk of breast and ovarian cancer. We explored possible hormone-mediated mechanisms for these associations by examining the relationship between use of aspirin, non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen and sex steroid hormone concentrations among 740 postmenopausal women in the Nurses' Health Study. All women reported their analgesic use in 1988 or 1990 and provided a blood sample in 1989-90. We calculated adjusted geometric mean estrogen and androgen levels for each category of analgesic use, and calculated the *p*-value for trend with increasing frequency of use. There was no association between days of use per month of aspirin, non-aspirin NSAIDs, or acetaminophen in 1990 and hormone levels (all *p*-trend $\geq$ 0.09). However, we observed significant inverse trends between the estimated number of aspirin tablets per month in 1988 and concentrations of estrone (*p*-trend=0.04) and estrone sulfate (*p*-trend=0.03). In analyses of total (aspirin and non-aspirin) NSAID use in 1990, women who used NSAIDs at least 15 days per month had significantly lower levels of estradiol compared to women with no NSAID use (*p*-trend=0.03). Frequency of use of all analgesics (aspirin, non-aspirin NSAIDs, and acetaminophen) in 1990 was inversely associated with concentrations of estradiol (*p*-trend=0.001), free estradiol (*p*-trend=0.01), estrone sulfate (*p*-trend=0.03), and the ratio of estradiol to testosterone (*p*-trend=0.04). Among postmenopausal women, regular users of aspirin and other analgesics may have lower estrogen levels than non-users, which could contribute to a decreased risk of breast or ovarian cancer among analgesic users.

Keywords

Aspirin; NSAIDs; acetaminophen; estrogens; androgens

Introduction

Regular use of aspirin, non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen has been inversely associated with risk of breast and ovarian cancer in some epidemiologic studies (1-11); however, overall the data are inconclusive and the potential

mechanisms are unclear. Meta-analyses generally suggest that use of aspirin or non-aspirin NSAIDs decreases breast cancer risk by 12 to 25% (1-6). NSAID use also has been inversely associated with ovarian cancer risk in a few studies (7-10), but meta-analyses generally have not supported an association (2,12,13). Acetaminophen does not appear to influence breast cancer risk (5,14) but has been inversely associated with risk of ovarian cancer in some (11), but not all (15,16), studies.

Analgesics may inhibit breast or ovarian carcinogenesis in part by influencing hormone levels. Aspirin and non-aspirin NSAIDs inhibit activity of aromatase, an enzyme involved in the conversion of androgens to estrogens, by decreasing cyclooxygenase (COX) expression and prostaglandin synthesis (17). Expression of the aromatase gene (*CYP19*) has been positively correlated with *COX-1* and *COX-2* expression in human breast tissue (18). Acetaminophen has lower anti-inflammatory activity and is not considered an NSAID, although it appears to inhibit the COX-1 and COX-2 enzymes under certain conditions (19-21). Other properties of acetaminophen that could contribute to an inverse association with breast and/or ovarian cancer risk include an antigonadotropic effect via glutathione depletion and decreased follicle-stimulating hormone (FSH) concentrations, or hormone-agonist/-antagonist activity due to chemical similarity to estradiol and progesterone (22).

Given the possible hormone-mediated mechanisms for an inverse association between analgesic use and risk of breast or ovarian cancer, we examined the cross-sectional relationship between use of aspirin, non-aspirin NSAIDs, and acetaminophen and sex steroid hormone concentrations among 740 postmenopausal women in the Nurses' Health Study (NHS).

Materials and Methods

Study Population

The NHS was established in 1976 when 121,700 female registered nurses aged 30-55 responded to a mailed questionnaire about their lifestyle factors and medical histories. Study participants completed follow-up questionnaires every two years, providing information on new diagnoses of disease and updated information on risk factors.

In 1989-90, when participants were 43 to 70 years of age, 32,826 women provided a blood sample. Details of the collection are described elsewhere (23). Briefly, participants arranged to have their blood drawn and shipped with an icepack via overnight mail. Upon receipt at our laboratory, each blood specimen was processed and stored in continuously-monitored liquid nitrogen freezers at a temperature of -130°C or colder. At the time of blood collection, participants completed a short questionnaire that included questions on current weight, postmenopausal hormone (PMH) use, and menopausal status.

Women included in this analysis were controls in a nested case-control study of breast cancer (24,25). All participants were postmenopausal, had not used PMH within three months prior to blood collection, had no history of cancer, and reported their analgesic use on the 1988 or 1990 questionnaire. Women were considered postmenopausal if they reported having a natural menopause (no menstrual cycles during the previous 12 months) or a bilateral oophorectomy, or if they had a hysterectomy without bilateral oophorectomy and were ≥ 56 (for non-smokers) or ≥ 54 (for smokers) years of age (26). The Committee on the Use of Human Subjects in Research at Brigham and Women's Hospital, Boston, MA approved this analysis.

Exposure and Covariate Data

In 1988, the questionnaire requested information on the frequency of aspirin use (never, 1-4, 5-14, 15-21, or ≥ 22 days per month), and the usual number of tablets per day of use (0, 1, 2, 3-4, 5-6, or ≥ 7 tablets). In 1990 and 1992, we requested the average number of days of use per

month of acetaminophen, aspirin, and other anti-inflammatory drugs, using the same categories as the 1988 questionnaire. In our analyses we combined the top two frequency categories (15-21 and ≥ 22 days/month), due to the small number of women who reported 15-21 days of use per month.

We obtained information on covariates of interest from the biennial questionnaires or the questionnaire completed at blood draw. We calculated body mass index (BMI) using weight reported at blood draw and height reported on the baseline (1976) questionnaire. If weight at blood draw was missing, we used the value from the 1990 questionnaire to calculate BMI. Physical activity was reported in 1988 and alcohol intake in 1990. Parity and age at first birth were collected through 1984. Age at menopause was collected on every biennial questionnaire, and in our analysis we used each participant's first reported age at menopause. Smoking history was assessed in 1990, and data on PMH use were collected both at blood draw and in 1990.

Laboratory Assays

Details of the laboratory methods are described elsewhere (24,27). Briefly, plasma levels of each hormone were assayed in up to six batches. Estradiol, estrone, androstenedione, and testosterone were measured at Quest Diagnostics' Nichols Institute (San Juan Capistrano, CA) using radioimmunoassay, after extraction and column chromatography. For estrone sulfate, the first batch was assayed at the University of Massachusetts Medical Center's Longcope Steroid Radioimmunoassay Laboratory (Worcester, MA), and subsequent batches were assayed at the Nichols Institute. Estrone sulfate concentrations were determined by radioimmunoassay of estrone, after enzyme hydrolysis, extraction, and column chromatography. For sex hormone-binding globulin (SHBG), which was used to calculate free estradiol and free testosterone, the first two batches were assayed at the Longcope Laboratory, and subsequent batches were assayed at the Reproductive Endocrinology Unit Laboratory at Massachusetts General Hospital (Boston, MA) using the AxSYM Immunoassay system (Abbott Diagnostics, Chicago, IL). Free estradiol and free testosterone were calculated using the methods of Sodergard et al. (28).

Estradiol, estrone sulfate, testosterone, and SHBG were assayed in controls matched to breast cancer cases diagnosed through June 2000, and estrone and androstenedione were assayed in controls matched to cases diagnosed through June 1998. We included 10% blinded replicates in each batch to assess laboratory precision. Within-batch coefficients of variation were between 8% and 10% for all analytes except androstenedione (12%). The limits of detection were 2 pg/mL for estradiol, 10 pg/mL for estrone, 40 pg/mL for estrone sulfate, 5 ng/dL for androstenedione, and 2 ng/dL for testosterone. When hormone values were reported as less than the detection limit, which occurred for estrone (n=13), estradiol (n=2), and estrone sulfate (n=5), we set the value to half the limit of detection.

Statistical Analysis

For each hormone, we excluded from the analysis women with missing data due to assay difficulties or low sample volume. In addition, we excluded six participants with outlying values for estradiol (n=1), androstenedione (n=2), or testosterone (n=3), based on the generalized extreme studentized deviate many-outlier detection approach (29). For each analysis we also excluded women who were missing data on the exposure of interest. After these exclusions, 740 women were eligible for our analyses.

We log-transformed the values for each hormone to improve normality, and used generalized linear models to calculate adjusted geometric means for each hormone by category of analgesic use in 1988 or 1990. We calculated the percent difference in the geometric means for the highest versus lowest category of use of each analgesic as $(e^{\beta}-1)*100$. In addition, we modeled a

continuous variable weighted by the midpoint of each frequency category, and calculated the *p*-value for trend using the Wald test (30).

We created exposure variables for the estimated number of aspirin tablets per month in 1988 and the frequency (days/month) of total NSAID or total analgesic use in 1990. We calculated the number of aspirin tablets per month by multiplying the number of days of use per month by the usual number of tablets per day of use, using the midpoint of each category. We calculated the frequency of use of aspirin plus non-aspirin NSAIDs or all analgesics combined (aspirin, non-aspirin NSAIDs, and acetaminophen) by summing the midpoints of the frequency categories for each analgesic of interest.

We adjusted all models for laboratory batch, age at blood draw (continuous), fasting status (<10 vs. ≥10 hours), date (≤6/89, 7/89-12/89, 1/90-6/90, ≥7/90) and time of day (1-8 a.m., 9 a.m.-noon, 1-4 p.m., 5 p.m.-midnight) of blood draw, age at first birth (AFB)/parity (nulliparous, AFB <25/1-4 children, AFB 25-29/1-4 children, AFB ≥30/1-4 children, AFB <25/≥5 children, AFB ≥25/≥5 children), BMI (continuous), physical activity (<3, 3-<9, 9-<18, 18-<27, ≥27 MET-hours/week), smoking history (never, past, current), duration of PMH use among past users (continuous), age at menopause (<45, 45-49, 50-54, ≥55), and alcohol intake (0, >0-10, >10-20, >20-30, >30 grams/day). Additionally, in the analyses of aspirin, non-aspirin NSAID, acetaminophen, and total NSAID use in 1990, we adjusted for frequency of use of other analgesics using the categories noted above. We also considered other potential confounders, including duration of breastfeeding, duration of past oral contraceptive use, age at menarche, and hysterectomy without bilateral oophorectomy; however, these variables did not change the results and therefore were not included in our final model.

We assessed whether the association between each analgesic and hormone levels differed by category of physical activity (<9 vs. ≥9 MET-hours/week), PMH use (never vs. ever), time since menopause (<10 vs. ≥10 years), and BMI (<25 vs. ≥25 kg/m²), a major determinant of hormone levels in postmenopausal women (23,31). We tested for effect modification by modeling an interaction term between each potential modifier of interest and a continuous variable weighted by the midpoint of each category of analgesic use frequency, and calculating the Wald test. Finally, we examined the associations among women with consistent analgesic use by limiting the analysis to women who reported regular use (≥5 days/month) of the same analgesic in both 1988 and 1990 (aspirin only) or 1990 and 1992, or infrequent use (0 to 4 days/month) at both time points. All *p*-values were two-sided and considered statistically significant if ≤0.05.

Results

The mean age at blood draw was 61.5 years (Table 1). On average, participants were slightly overweight and moderately physically active. Regular aspirin use (>once/week) (31.2%) was more common than regular use of acetaminophen (17.3%) or non-aspirin NSAIDs (19.1%) in 1990. Regular aspirin use was slightly lower in 1988 than in 1990; in 1988, 29.3% of participants reported regular aspirin use, while 20.8% reported regular use in both 1988 and 1990 and 59.1% reported no use or use ≤once per week at both time points. Frequency of aspirin use in 1988 was moderately correlated with use in 1990 (Spearman *r*=0.65), while correlations between use of the different types of analgesics in 1990 were weak (Spearman *r*=0.01-0.22).

There were no associations between the number of days of use per month of aspirin, non-aspirin NSAIDs, or acetaminophen in 1990 and levels of estrogens, androgens, or the ratio of estrogens to androgens (Table 2). However, using the more detailed data on aspirin use from 1988, we observed significant inverse trends between the estimated number of aspirin tablets per month and concentrations of estrone (*p*-trend=0.04) and estrone sulfate (*p*-trend=0.03) (Table 3).

There were no statistically significant differences in hormone levels among women in the highest versus lowest category of aspirin use for any of the hormones examined (results not shown).

In analyses of frequency of total (aspirin plus non-aspirin) NSAID use in 1990, we observed significant inverse associations with estradiol and free estradiol and a borderline significant inverse association with estrone sulfate (Table 4). Mean estradiol levels were 10.5% lower among women who used NSAIDs at least 15 days per month, compared to women with no NSAID use (6.4 vs. 7.2 pg/mL, respectively; p -trend=0.03). Similarly, mean concentrations of free estradiol were 10.6% lower (0.09 vs. 0.10 pg/mL, respectively; p -trend=0.04) and mean estrone sulfate levels were 11.1% lower (188 vs. 211 pg/mL, respectively; p -trend=0.07) among women in the highest versus lowest category of NSAID use. These associations were strengthened when we added acetaminophen and considered use of all analgesics combined in 1990 (Table 4). Women in the highest versus lowest category of total analgesic use had significantly lower levels of estradiol (15.2% lower; p -trend=0.001) and free estradiol (12.9% lower; p -trend=0.01), and a lower ratio of estradiol to testosterone (4.1% lower; p -trend=0.04). In addition, we observed a significant inverse trend between frequency of total analgesic use and estrone sulfate (p -trend=0.03), but the difference in estrone sulfate levels for women in the highest versus lowest category of total analgesic use (12.6% lower) was not statistically significant.

The primary confounder in our analysis was BMI. When we adjusted our models for age, laboratory batch, and date, time, and fasting status of blood draw only (age-adjusted model), none of the analgesic/hormone associations were statistically significant. For example, women in the highest versus lowest category of total analgesic use had 4.4% lower levels of estradiol in the age-adjusted model, compared to 15.2% lower in the final multivariable-adjusted model, and the p -values for trend were 0.31 and 0.001, respectively. However, after adding BMI to the age-adjusted model, the results were similar to those for the final model; for the association with total analgesic use, estradiol concentrations were 14.9% lower among women in the highest versus lowest category of use, and the p -trend was 0.001. All of the significant associations from the final multivariable-adjusted model remained statistically significant in the model adjusted for age, laboratory batch, date/time/fasting status of blood draw, and BMI (results not shown). Supplementary Table 1 shows the percent difference in hormone levels for women in the highest versus lowest category of analgesic use in 1990 and the p -value for trend, before and after adjustment for BMI.

In addition to the covariates in our final model, we also examined potential confounding by conditions that may influence analgesic use, including fracture, hypertension, rheumatoid arthritis, and uterine fibroids. However, adjusting for these preexisting conditions did not materially change our results (results not shown).

We observed significant interactions with BMI for several associations (Supplementary Table 2). In stratified analyses, the association between aspirin use in 1990 and free estradiol was inverse only among women with BMI <25 kg/m² (p -interaction=0.005); comparing women in the highest versus lowest category of aspirin use, the percent difference in free estradiol levels was -19.4% (p -trend=0.01) among lean women and +4.9% (p -trend=0.61) among overweight women. However, other associations were similar by BMI category or were more strongly inverse among overweight women, and there was no clear pattern of interactions with BMI across the different analgesics and hormones. Although there were a few significant interactions with physical activity, PMH use, and time since menopause, there was no consistent pattern of effect modification by these variables (results not shown).

Among women (n=329-545) with consistent analgesic use across two follow-up cycles, the results generally were similar to those for all women (results not shown). However, some associations were no longer statistically significant, likely due to the smaller sample size. In secondary analyses, results after excluding women within four years of menopause (n=60) were similar to those for all women (results not shown).

Although our analyses were based on a priori hypotheses, we secondarily evaluated the statistical significance of the results after adjustment for multiple comparisons. Using the conservative Bonferroni correction with 28 unique exposure/hormone combinations, the adjusted alpha level was $0.05/28 = 0.002$. At this level of significance, only the association between total analgesic use and estradiol remained statistically significant (p -trend=0.001).

Discussion

Our results suggest that postmenopausal women who regularly use aspirin, non-aspirin NSAIDs, or acetaminophen may have lower estrogen levels than women who infrequently use analgesics. We observed significant inverse associations between total NSAID use and concentrations of estradiol and free estradiol and between total analgesic use and levels of estradiol, free estradiol, estrone sulfate, and the ratio of estradiol to testosterone. There were no associations with frequency of use (days/month) of each individual type of analgesic in 1990, when data on the number of tablets per day were unavailable; however, we observed significant inverse associations between the estimated number of aspirin tablets per month in 1988 and concentrations of estrone and estrone sulfate. Although some associations varied by category of BMI, physical activity, PMH use, or time since menopause, there was no clear pattern of effect modification by any of these variables.

Two previous studies have examined the association between NSAID use and hormone levels in postmenopausal women. In an analysis of 274 participants in the Women's Health Initiative Dietary Modification Trial, regular use of NSAIDs (defined as use at least twice per week) was not significantly associated with levels of estrogens, testosterone, or androstenedione (32). However, this study did not examine associations with dose or frequency of NSAID use, and participants were asked to refrain from using NSAIDs during the 48 hours prior to blood draw, which may have limited the ability to detect associations. In another study of NSAID use and estradiol levels among 260 women, both current use reported at blood draw and consistent use (defined as self-reported current use plus use within 48 hours prior to blood draw) were inversely associated with serum levels of total estradiol (33). Associations with dose and frequency of NSAID use were not assessed. Neither study evaluated interactions with BMI or other potential effect modifiers.

Aromatase inhibition due to decreased prostaglandin synthesis is a plausible mechanism by which analgesics may decrease risk of hormone-related cancers in women. In the presence of inflammation and other stimuli, COX-2 expression is upregulated and levels of prostaglandins, particularly PGE₂, rise (17). Human adipose stromal cells exposed to PGE₂ have higher levels of cyclic AMP (cAMP) and a 50-fold increase in aromatase activity, compared to control cells, due to cAMP-induced stimulation of the *CYP19* promoter II (34). The aromatase enzyme catalyzes the conversion of testosterone to estradiol and androstenedione to estrone; in postmenopausal women, adipose aromatase is the primary source of circulating estrogens (35,36). Multiple studies have observed strong positive associations between levels of endogenous estrogens and breast cancer risk in postmenopausal women (37). In contrast, data on endogenous estrogen concentrations and ovarian cancer risk are sparse (37); however, studies of genetic variation in the *CYP19* gene (38) and studies of estrogen-related exposures, such as BMI and PMH (39), suggest a possible role of estrogens in ovarian carcinogenesis, particularly for the endometrioid histologic subtype (40,41). Aromatase inhibitors, which are

used in the treatment of estrogen receptor-positive postmenopausal breast cancer, significantly decrease estrogen concentrations without altering androgen concentrations (42). This suggests that analgesics that decrease aromatase activity via suppression of COX expression and prostaglandin synthesis also may decrease estrogen concentrations and potentially risk of breast or ovarian cancer. Several studies of NSAID use and breast cancer risk have reported an inverse association only for hormone-receptor positive breast tumors (43-45), supporting the aromatase inhibition hypothesis, but other studies have reported no difference by hormone receptor status (5,46-50).

Although we observed significant inverse associations between several analgesic variables and estrogen concentrations, not all of our results were consistent with those expected if analgesics influence hormone levels via aromatase inhibition. In particular, there was no association between frequency of use of aspirin, non-aspirin NSAIDs, or acetaminophen individually in 1990 and levels of any estrogen. In addition, the estimated number of aspirin tablets per month in 1988 was significantly inversely associated with estrone and estrone sulfate concentrations but not levels of estradiol or free estradiol, although the observed associations were in the hypothesized direction. Limitations of our data that may have contributed to these inconsistencies include the unavailability of information on the exact frequency of use or dose of each analgesic in 1990, and the availability of a single blood sample for each woman. However, the intraclass correlation coefficients for within-person repeated measures of these hormones over time are high (51), suggesting that a single blood sample reflects long-term values. Although analgesic use reported at the time of the 1988 or 1990 questionnaire may not have accurately reflected use at the time of blood draw, the results were essentially unchanged in analyses restricted to women who were consistent analgesic users across two follow-up cycles and who were therefore more likely to have had the same level of use at blood draw. While our study population is large, we may have had inadequate power to detect small differences in hormone levels, particularly for analyses of the extreme categories of analgesic use where the number of women in the highest frequency category is relatively small. The cross-sectional design also is a limitation of our analysis, as it is impossible to determine whether differences in hormone levels were related to analgesic use or some other factor, such as a preexisting condition influencing both hormone levels and analgesic use. Although there was no evidence of confounding by several conditions examined, including fracture, hypertension, rheumatoid arthritis, and uterine fibroids, it is possible that other conditions may have confounded the associations. According to supplementary data collected for a subset of participants (52), the most common indications for frequent analgesic use in 1999 were muscle/joint pain, cardiovascular prevention (aspirin only), headache, and backache. While the indications for use at the time of blood draw may have differed slightly from those in 1999, these conditions, with the possible exception of headaches (53), are unlikely to be strongly related to estrogen concentrations.

This analysis also has several strengths, including the large study population with data on multiple hormones of interest, and the detailed information on analgesic use and potential confounders of interest collected near the time of blood draw. In addition, with the exception of BMI, which we controlled for continuously, there was minimal confounding by the covariates included in our analysis, making it unlikely that the results were due to residual confounding.

Our results provide modest support for an inverse association between analgesic use and estrogen concentrations in postmenopausal women. Additional research is needed to confirm this association and to determine whether the decrease in estrogen concentrations due to analgesic use translates to a lower risk of breast or ovarian cancer. Randomized trials of aspirin, non-aspirin NSAID, and acetaminophen use and changes in hormone levels would be a logical next step in elucidating these associations, including the magnitude of the effect, the most

beneficial analgesics, and the relevant dose. This research may have important public health implications if an inverse association between analgesic use and risk of breast or ovarian cancer is confirmed, as analgesics could be easily implemented as a chemopreventive and may decrease risk of several cancers.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Supported by research grants P01 CA87969 and R01 CA49449 from the National Cancer Institute. M.G. was supported by training grants T32 CA009001 and R25 CA098566.

References

1. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a meta-analysis. *Br J Cancer* 2001;84:1188–92. [PubMed: 11336469]
2. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. *BMC Cancer* 2003;3:28. [PubMed: 14588079]
3. Mangiapane S, Blettner M, Schlattmann P. Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. *Pharmacoepidemiol Drug Saf* 2008;17:115–24. [PubMed: 17955496]
4. Takkouche B, Regueira-Mendez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. *J Natl Cancer Inst* 2008;100:1439–47. [PubMed: 18840819]
5. Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II. *Arch Intern Med* 2009;169:115–21. [PubMed: 19171806]
6. Zhao YS, Zhu S, Li XW, et al. Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. *Breast Cancer Res Treat* 2009;117:141–50. [PubMed: 18979210]
7. Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE. Aspirin, other NSAIDs, and ovarian cancer risk (United States). *Cancer Causes Control* 2002;13:535–42. [PubMed: 12195643]
8. Rosenberg L, Palmer JR, Rao RS, et al. A case-control study of analgesic use and ovarian cancer. *Cancer Epidemiol Biomarkers Prev* 2000;9:933–7. [PubMed: 11008911]
9. Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A. Analgesic drug use and risk of ovarian cancer. *Epidemiology* 2006;17:104–7. [PubMed: 16357602]
10. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. *Br J Cancer* 2008;98:1781–3. [PubMed: 18506182]
11. Bonovas S, Filioussi K, Sitaras NM. Paracetamol use and risk of ovarian cancer: a meta-analysis. *Br J Clin Pharmacol* 2006;62:113–21. [PubMed: 16842383]
12. Bonovas S, Filioussi K, Sitaras NM. Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis *Br J Clin Pharmacol* 2005;60:194–203.
13. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an updated quantitative review to 2005. *Cancer Causes Control* 2006;17:871–88. [PubMed: 16841255]
14. Moysich KB, Beehler GP, Zirpoli G, Choi JY, Baker JA. Use of common medications and breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2008;17:1564–95. [PubMed: 18628410]
15. Hannibal CG, Rossing MA, Wicklund KG, Cushing-Haugen KL. Analgesic drug use and risk of epithelial ovarian cancer. *Am J Epidemiol* 2008;167:1430–7. [PubMed: 18390840]
16. Pinheiro SP, Tworoger SS, Cramer DW, Rosner BA, Hankinson SE. Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. *Am J Epidemiol* 2009;169:1378–87. [PubMed: 19342401]

17. Diaz-Cruz ES, Brueggemeier RW. Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. *Anticancer Agents Med Chem* 2006;6:221–32. [PubMed: 16712450]
18. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. *Cancer Lett* 1999;140:27–35. [PubMed: 10403538]
19. Graham GG, Scott KF. Mechanism of action of paracetamol. *Am J Ther* 2005;12:46–55. [PubMed: 15662292]
20. Boutaud O, Aronoff DM, Richardson JH, Marnett LJ, Oates JA. Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H(2) synthases. *Proc Natl Acad Sci U S A* 2002;99:7130–5. [PubMed: 12011469]
21. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. *FASEB J* 2008;22:383–90. [PubMed: 17884974]
22. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. *Lancet* 1998;351:104–7. [PubMed: 9439495]
23. Hankinson SE, Willett WC, Manson JE, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. *J Natl Cancer Inst* 1995;87:1297–302. [PubMed: 7658481]
24. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. *J Natl Cancer Inst* 2004;96:1856–65. [PubMed: 15601642]
25. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk? *J Clin Oncol* 2006;24:1823–30. [PubMed: 16567770]
26. Hankinson SE, Willett WC, Michaud DS, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. *J Natl Cancer Inst* 1999;91:629–34. [PubMed: 10203283]
27. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. *J Natl Cancer Inst* 1998;90:1292–9. [PubMed: 9731736]
28. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. *J Steroid Biochem* 1982;16:801–10. [PubMed: 7202083]
29. Rosner B. Percentage points for a generalized ESD many-outlier procedure. *Technometrics* 1983;25:165–72.
30. Hosmer, DW.; Lemeshow, S. *Applied Logistic Regression*. New York: John Wiley & Sons; 1989.
31. McTiernan A, Wu L, Chen C, et al. Relation of BMI and physical activity to sex hormones in postmenopausal women. *Obesity (Silver Spring)* 2006;14:1662–77. [PubMed: 17030978]
32. McTiernan A, Wu L, Barnabei VM, et al. Relation of demographic factors, menstrual history, reproduction and medication use to sex hormone levels in postmenopausal women. *Breast Cancer Res Treat* 2008;108:217–31. [PubMed: 18297397]
33. Hudson AG, Gierach GL, Modugno F, et al. Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women. *Cancer Epidemiol Biomarkers Prev* 2008;17:680–7. [PubMed: 18349287]
34. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. *Endocrinology* 1996;137:5739–42. [PubMed: 8940410]
35. Miller, WL.; Styne, DM. Female puberty and its disorders. In: Yen, SSC.; Jaffe, RB.; Barbieri, RL., editors. *Reproductive Endocrinology*. 4th. Philadelphia: W.B. Saunders Company; 1999. p. 388–412.
36. Hankinson SE. Endogenous hormones and risk of breast cancer in postmenopausal women. *Breast Dis* 2005;24:3–15. [PubMed: 16917136]
37. Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. *Adv Exp Med Biol* 2008;630:148–65. [PubMed: 18637490]
38. Kotsopoulos J, Vitonis AF, Terry KL, et al. Coffee intake, variants in genes involved in caffeine metabolism, and the risk of epithelial ovarian cancer. *Cancer Causes Control* 2009;20:335–44. [PubMed: 18941913]

39. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. *Cancer Epidemiol Biomarkers Prev* 2005;14:98–107. [PubMed: 15668482]
40. Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk Factors for Epithelial Ovarian Cancer by Histologic Subtype. *Am J Epidemiol*. 2009 Epub ahead of print.
41. Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. A prospective study of postmenopausal hormone use and ovarian cancer risk. *Br J Cancer* 2007;96:151–6. [PubMed: 17179984]
42. Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. *Endocr Rev* 2005;26:331–45. [PubMed: 15814851]
43. Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. *JAMA* 2004;291:2433–40. [PubMed: 15161893]
44. Marshall SF, Bernstein L, Anton-Culver H, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. *J Natl Cancer Inst* 2005;97:805–12. [PubMed: 15928301]
45. Gierach GL, Lacey JV Jr, Schatzkin A, et al. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. *Breast Cancer Res* 2008;10:R38. [PubMed: 18447943]
46. Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. *Am J Epidemiol* 2005;162:165–70. [PubMed: 15972932]
47. Gallicchio L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ. Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. *Int J Cancer* 2007;121:211–15. [PubMed: 17330846]
48. Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN. Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. *Am J Epidemiol* 2007;166:1150–8. [PubMed: 17698973]
49. Kirsh VA, Kreiger N, Cotterchio M, Sloan M, Theis B. Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. *Am J Epidemiol* 2007;166:709–16. [PubMed: 17660454]
50. Friis S, Thomassen L, Sorensen HT, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. *Eur J Cancer Prev* 2008;17:88–96. [PubMed: 18287865]
51. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. *Cancer Epidemiol Biomarkers Prev* 1995;4:649–54. [PubMed: 8547832]
52. Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime nonnarcotic analgesic use and decline in renal function in women. *Arch Intern Med* 2004;164:1519–24. [PubMed: 15277282]
53. Mathes RW, Malone KE, Daling JR, et al. Migraine in postmenopausal women and the risk of invasive breast cancer. *Cancer Epidemiol Biomarkers Prev* 2008;17:3116–22. [PubMed: 18990752]

Table 1
Characteristics at blood draw of 740 postmenopausal women in the Nurses' Health Study

	Mean (SD) or %
Age (years)	61.5 (4.7)
Body mass index (kg/m ²)	26.2 (4.8)
Physical activity (mets/week)	15.7 (19.3)
Parous, %	95.0
Parity (among parous women)	3.6 (1.7)
Age at first birth in years (among parous women)	25.8 (3.5)
Age at natural menopause (years)	50.5 (3.2)
Past post-menopausal hormone (PMH) use, %	31.2
Duration of PMH use among past users (months)	35.5 (44.4)
Alcohol intake (grams/day)	5.4 (10.3)
Current smoker, %	13.1
Regular aspirin use [*] , %	31.2
Regular use of non-aspirin NSAIDs [*] , %	19.1
Regular acetaminophen use [*] , %	17.3
	Median (10th-90th percentile)
Estradiol, pg/mL	7 (4 - 14)
Free estradiol, pg/mL	0.10 (0.04 - 0.25)
Estrone, pg/mL	25 (14 - 43)
Estrone sulfate, pg/mL	197 (86 - 522)
Testosterone, ng/dL	22 (12 - 39)
Free testosterone, ng/dL	0.21 (0.09 - 0.44)
Androstenedione, ng/dL	57 (29 - 109)
Ratio of estrone/androstenedione	0.43 (0.22 - 0.78)
Ratio of estradiol/testosterone	0.31 (0.16 - 0.61)

* Use more than once per week in 1990

Table 2
Adjusted geometric mean hormone levels by frequency of analgesic use in 1990 among postmenopausal women in the Nurses' Health Study*

	N	Frequency of use (days/mo) [†]					Percent difference [‡]	p-value for trend [§]
		0	1-4	5-14	15+			
Aspirin								
Maximum N	638	300	139	69	130			
Estradiol, pg/mL	617	6.9	7.2	7.0	6.6	-3.6		0.37
Free estradiol, pg/mL	588	0.10	0.10	0.10	0.09	-2.7		0.45
Estrone, pg/mL	485	24.1	24.7	24.2	26.5	10.1		0.11
Estrone sulfate, pg/mL	616	203	211	234	194	-4.5		0.51
Testosterone, ng/dL	621	21.4	22.0	20.5	22.0	2.8		0.77
Free testosterone, ng/dL	606	0.20	0.22	0.20	0.21	5.9		0.76
Androstenedione, ng/dL	484	54.4	56.0	52.3	61.3	12.8		0.11
Ratio of estrone/androstenedione	462	0.47	0.46	0.48	0.47	0.30		0.85
Ratio of estradiol/testosterone	588	0.36	0.35	0.37	0.33	-2.7		0.24
Non-aspirin NSAIDs								
Maximum N	596	387	95	35	79			
Estradiol, pg/mL	581	7.0	7.2	5.7	6.4	-8.9		0.14
Free estradiol, pg/mL	553	0.10	0.10	0.08	0.09	-11.4		0.12
Estrone, pg/mL	464	24.8	23.8	21.3	24.0	-3.1		0.66
Estrone sulfate, pg/mL	573	207	230	176	183	-11.3		0.12
Testosterone, ng/dL	579	21.5	22.5	19.9	19.8	-7.8		0.18
Free testosterone, ng/dL	564	0.21	0.22	0.19	0.18	-12.1		0.09
Androstenedione, ng/dL	462	55.1	57.2	53.0	51.4	-6.8		0.34
Ratio of estrone/androstenedione	443	0.49	0.45	0.44	0.47	-1.1		0.84
Ratio of estradiol/testosterone	551	0.36	0.35	0.31	0.34	-1.7		0.44
Acetaminophen								
Maximum N	606	339	162	47	58			
Estradiol, pg/mL	588	7.2	6.7	7.0	6.4	-9.9		0.23
Free estradiol, pg/mL	558	0.10	0.10	0.10	0.09	-7.9		0.47
Estrone, pg/mL	472	24.9	25.4	24.2	22.7	-8.9		0.19

	Frequency of use (days/mo) [†]					Percent difference [‡]	<i>p</i> -value for trend [§]
	N	0	1-4	5-14	15+		
Estrone sulfate, pg/mL	583	213	213	176	190	-10.8	0.14
Testosterone, ng/dL	589	21.0	21.3	22.3	21.7	3.7	0.55
Free testosterone, ng/dL	572	0.20	0.21	0.23	0.21	5.2	0.44
Androstenedione, ng/dL	471	54.4	57.6	58.6	53.0	-2.7	0.79
Ratio of estrone/androstenedione	451	0.49	0.46	0.47	0.45	-4.3	0.26
Ratio of estradiol/testosterone	559	0.37	0.35	0.34	0.34	-3.2	0.18

* Adjusted for age at blood draw, laboratory batch, fasting status at blood draw, date and time of blood draw, parity, age at first birth, BMI at blood draw, physical activity, smoking history, duration of postmenopausal hormone use among past users, age at menopause, alcohol intake, and frequency of use of other analgesics

[†] Top two frequency categories (15-21 and ≥22 days/month) are combined, due to small number of women who reported 15-21 days of use per month

[‡] Percent difference for highest versus lowest category of use (15+ vs. 0 days/month), calculated using $(e^{\beta}-1)*100$; no statistically significant differences

[§] Weighted by the midpoint of each frequency category (0, 2.5, 9.5, or 23 days/month) and calculated using the Wald test

Table 3
Adjusted geometric mean hormone levels by estimated number of aspirin tablets per month in 1988 among postmenopausal women in the Nurses' Health Study*

	N	Estimated aspirin tablets/month [†]					Percent difference [‡]	p-value for trend [§]
		0	1-10	11-30	31-50	50+		
Maximum N	716	276	247	100	25	68		
Estradiol, pg/mL	694	7.0	6.9	7.2	6.7	6.6	-4.5	0.45
Free estradiol, pg/mL	663	0.10	0.10	0.10	0.10	0.09	-5.8	0.39
Estrone, pg/mL	545	24.7	25.2	24.2	23.4	22.7	-7.9	0.04
Estrone sulfate, pg/mL	687	204	216	207	213	179	-12.1	0.03
Testosterone, ng/dL	697	21.3	21.9	21.1	19.3	20.5	-3.7	0.08
Free testosterone, ng/dL	681	0.20	0.22	0.20	0.19	0.19	-6.0	0.12
Androstenedione, ng/dL	545	55.4	56.8	55.5	53.3	53.0	-4.4	0.07
Ratio of estrone/androstenedione	522	0.47	0.48	0.45	0.45	0.47	-0.02	0.68
Ratio of estradiol/testosterone	659	0.35	0.35	0.36	0.40	0.34	-1.0	0.72

* Adjusted for age at blood draw, laboratory batch, fasting status at blood draw, date and time of blood draw, parity, age at first birth, BMI at blood draw, physical activity, smoking history, duration of postmenopausal hormone use among past users, age at menopause, and alcohol intake

[†] Calculated as the midpoint of each frequency category (0, 2.5, 9.5, 18, or 26 days/month) multiplied by the midpoint of each category of usual number of tablets taken on each day of use (0, 1, 2, 3.5, 5.5, or 7.5 tablets)

[‡] Percent difference for highest versus lowest category of aspirin use (50+ vs. 0 tablets/month), calculated using $(e^{\beta}-1)*100$; no statistically significant differences

[§] Weighted by the midpoint of each frequency category (0, 2.5, 9.5, 18, or 26 days/month) multiplied by the midpoint of each category of usual number of tablets taken on each day of use (0, 1, 2, 3.5, 5.5, or 7.5 tablets); calculated using the Wald test

Table 4
Adjusted geometric mean hormone levels by frequency of total NSAID or total analgesic use in 1990 among postmenopausal women in the Nurses' Health Study*

	Frequency of use (days/mo) [†]					Percent difference [‡]	p-value for trend [§]
	N	0	1-4	5-14	15+		
Aspirin and non-aspirin NSAID use [§]							
Maximum N	691	230	154	107	200		
Estradiol, pg/mL	670	7.2	7.1	7.1	6.4	-10.5**	0.03
Free estradiol, pg/mL	638	0.10	0.10	0.10	0.09	-10.6	0.04
Estrone, pg/mL	528	24.7	23.5	24.9	24.6	-0.11	0.74
Estrone sulfate, pg/mL	665	211	211	221	188	-11.1	0.07
Testosterone, ng/dL	671	21.9	21.8	20.6	21.0	-4.3	0.35
Free testosterone, ng/dL	655	0.21	0.22	0.20	0.20	-4.3	0.26
Androstenedione, ng/dL	526	55.3	54.8	54.1	56.2	1.6	0.75
Ratio of estrone/androstenedione	504	0.48	0.45	0.49	0.47	-1.3	0.91
Ratio of estradiol/testosterone	635	0.37	0.35	0.37	0.34	-3.0	0.15
Total analgesic use ^{§†}							
Maximum N	719	148	168	156	247		
Estradiol, pg/mL	698	7.5	7.1	7.1	6.3	-15.2**	0.001
Free estradiol, pg/mL	665	0.10	0.10	0.10	0.09	-12.9**	0.01
Estrone, pg/mL	554	25.0	24.5	24.6	24.3	-2.6	0.69
Estrone sulfate, pg/mL	692	216	210	222	189	-12.6	0.03
Testosterone, ng/dL	699	22.2	21.4	21.7	20.9	-5.8	0.32
Free testosterone, ng/dL	682	0.21	0.21	0.22	0.20	-2.1	0.59
Androstenedione, ng/dL	552	56.4	53.2	58.0	55.0	-2.5	0.99
Ratio of estrone/androstenedione	530	0.49	0.49	0.45	0.47	-1.6	0.44
Ratio of estradiol/testosterone	663	0.38	0.35	0.36	0.33	-4.1**	0.04

* Adjusted for age at blood draw, laboratory batch, fasting status at blood draw, date and time of blood draw, parity, age at first birth, BMI at blood draw, physical activity, smoking history, duration of postmenopausal hormone use among past users, age at menopause, and alcohol intake, plus frequency of use of acetaminophen for analyses of aspirin and non-aspirin NSAID use

[†] Top two frequency categories (15-21 and ≥22 days/month) are combined, due to small number of women who reported 15-21 days of use per month

[‡] Percent difference for highest versus lowest category of use (15+ vs. 0 days/month), calculated using $(e^{\beta}-1)*100$

[§] Calculated using the sum of variables for frequency of use of each relevant type of analgesic, where each variable was weighted by the midpoint of each frequency category (0, 2.5, 9.5, or 23 days/month)/*p*-value for trend weighted by the midpoint of each frequency category and calculated using the Wald test

^{||} Frequency of use of aspirin, non-aspirin NSAIDs, and acetaminophen

^{**} *p* ≤ 0.05